Solid biosciences reports fourth quarter and full-year 2021 financial results and 2-year efficacy and safety data from the ongoing phase i/ii ignite dmd clinical trial of sgt-001

- 2-year data from first three patients in the high dose (2e14 vg/kg) cohort suggest sustained or improved motor function, pulmonary function and clinically validated patient-reported outcomes compared with expected declines reported by natural history data -

SLDB Ratings Summary

SLDB Quant Ranking